NCT06698692 Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
| NCT ID | NCT06698692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Condition | ESCC |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-04-02 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-04-02 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Clinical data of patients with synchronous radiotherapy for esophageal cancer in the Department of Radiology of Jiangsu Provincial People's Hospital were collected. Patients were divided into trilaciclib group (34 cases) and control group (169 cases) based on whether trilaciclib was used or not. Patients in the trilaciclib group were given trilaciclib before each chemotherapy treatment. Propensity score matching (PSM) was used to balance the baseline characteristics between the two groups on a 1:1 ratio. After pairing, the rates of bone marrow suppression and other adverse events were compared between the two groups.
Eligibility Criteria
Inclusion Criteria: * age ≥18 years; * pathological diagnosis of esophageal squamous cell carcinoma; * failure to undergo surgical treatment; * completion of definitive chemoradiotherapy or chemoradiotherapy combined with immunotherapy. Exclusion Criteria: * history of other malignant tumors; * difficulty in follow-up; * insufficient clinical information.
Contact & Investigator
Xiao L Ge, PHD
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital with Nanjing Medical University
Frequently Asked Questions
Who can join the NCT06698692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ESCC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06698692 currently recruiting?
Yes, NCT06698692 is actively recruiting participants. Contact the research team at doctorsxl@163.com for enrollment information.
Where is the NCT06698692 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT06698692 clinical trial?
NCT06698692 is sponsored by The First Affiliated Hospital with Nanjing Medical University. The principal investigator is Xiao L Ge, PHD at The First Affiliated Hospital with Nanjing Medical University. The trial plans to enroll 200 participants.